{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:47Z","timestamp":1794097547800,"version":"4.8.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Weight loss associated with glucagon-like peptide-1 (GLP-1) agonists is frequently accompanied by reduced facial fat, sagging skin, and stubborn pockets of body fat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To identify aesthetic concerns related to GLP-1 agonist\u2013associated weight loss and current nonsurgical treatment trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>An electronic survey was sent to health care professionals (HCPs) who were part of 3 large, opt-in databases. HCPs must have had experience treating patients with aesthetic concerns after GLP-1 agonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The 406 HCPs who completed the survey (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 100 dermatologists,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 100 plastic surgeons,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 105 physicians in other specialties,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 101 nurses\/physician assistants) reported treating a mean of 1,249 cosmetic patients per year. HCPs reported a mean increase of 137% in the number of patients receiving GLP-1 agonists from 2023 to 2024. HCPs perceive midface volume loss, face\/neck skin laxity, and loose or sagging body skin to be the aesthetic changes most impacted by GLP-1 agonists, with patients also reportedly concerned about stubborn pockets of fat. Hyaluronic acid was considered the best treatment for facial concerns for an average of 47% of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>This large survey of HCPs representing various specialties provides insights into patient face- and body-related aesthetic concerns associated with GLP-1\u2013mediated weight loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005166","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:00:49Z","timestamp":1780045249000},"page":"S23-S28","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist\u2013Associated Weight Loss"],"prefix":"10.1097","volume":"52","author":[{"given":"Sabrina","family":"Fabi","sequence":"first","affiliation":[{"name":"Cosmetic Laser Dermatology, San Diego, California; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Yoo","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joely","family":"Kaufman-Janette","sequence":"additional","affiliation":[{"name":"Skin Associates of South Florida, Coral Gables, Florida; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Dayan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Illinois College of Medicine, Chicago, Illinois; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Boyd","sequence":"additional","affiliation":[{"name":"BOYD Beauty, Birmingham, Michigan; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sangha","sequence":"additional","affiliation":[{"name":"Associate Vice President of Medical Affairs and Head of US Medical Aesthetics, Allergan Aesthetics, an AbbVie company; Irvine, CA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Ashourian","sequence":"additional","affiliation":[{"name":"Medical Affairs, Allergan Aesthetics, an AbbVie company, Irvine, CA; USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.obpill.2024.100121","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: a narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes Pillars"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"e16716","DOI":"10.1111\/jocd.16716","article-title":"The role of GLP-1 agonists in esthetic medicine: exploring the impact of semaglutide on body contouring and skin health","volume":"24","author":"Haykal","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1055\/a-2148-6321","article-title":"Implications of Ozempic and other semaglutide medications for facial plastic surgeons","volume":"39","author":"Humphrey","year":"2023","journal-title":"Facial Plast Surg"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bjps.2023.04.057","article-title":"Ozempic face: a new challenge for facial plastic surgeons","volume":"81","author":"Tay","year":"2023","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"e5516","DOI":"10.1097\/GOX.0000000000005516","article-title":"Injectable weight loss medications in plastic surgery: what we know, perioperative considerations, and recommendations for the future","volume":"12","author":"O'Neill","year":"2024","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/PRS.0000000000012307","article-title":"Disruptions in aesthetic medicine: a global analysis of GLP-1 agonists using punctuated equilibrium framework","volume":"157","author":"Rahman","year":"2026","journal-title":"Plast Reconstr Surg"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/asj\/sjae085","article-title":"Prevalence patterns of body contouring procedures among injectable glucagon-like peptide-1 receptor agonist users","volume":"44","author":"Toms","year":"2024","journal-title":"Aesthet Surg J"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"ojae069","DOI":"10.1093\/asjof\/ojae069","article-title":"Soft tissue facial changes following massive weight loss secondary to medical and surgical bariatric interventions: a systematic review","volume":"6","author":"Jafar","year":"2024","journal-title":"Aesthet Surg J Open Forum"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00266-015-0540-6","article-title":"Objective assessment of facial rejuvenation after massive weight loss","volume":"39","author":"Couto","year":"2015","journal-title":"Aesthet Plast Surg"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1007\/s00266-025-05112-3","article-title":"Plastic surgery in the Ozempidemic: considerations for the timing of body contouring surgery in patients with semaglutide-associated weight loss","volume":"49","author":"Garbaccio","year":"2025","journal-title":"Aesthet Plast Surg"},{"key":"R17-20260730","doi-asserted-by":"crossref","first-page":"e3578","DOI":"10.1097\/GOX.0000000000003578","article-title":"Impact of minimally invasive aesthetic procedures on the psychological and social dimensions of health","volume":"9","author":"McKeown","year":"2021","journal-title":"Plast Reconstr Surg Glob Open"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:02:50Z","timestamp":1785384170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":16,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005166","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}